Solventum’s (SOLV) “Buy” Rating Reiterated at BTIG Research

BTIG Research reaffirmed their buy rating on shares of Solventum (NYSE:SOLV) in a research report sent to investors on Wednesday morning,Benzinga reports. They currently have a $89.00 target price on the stock.

A number of other research analysts also recently issued reports on SOLV. Weiss Ratings restated a “hold (c)” rating on shares of Solventum in a research report on Tuesday, January 27th. Rothschild & Co Redburn assumed coverage on shares of Solventum in a research report on Tuesday, March 24th. They issued a “sell” rating and a $60.00 price target on the stock. Piper Sandler dropped their price target on shares of Solventum from $98.00 to $92.00 and set an “overweight” rating on the stock in a research report on Friday, April 17th. KeyCorp dropped their price target on shares of Solventum from $99.00 to $92.00 and set an “overweight” rating on the stock in a research report on Monday, April 27th. Finally, Wall Street Zen downgraded shares of Solventum from a “buy” rating to a “hold” rating in a research report on Sunday, March 8th. Seven equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Solventum currently has a consensus rating of “Hold” and an average price target of $85.91.

Solventum Trading Up 2.3%

SOLV opened at $73.30 on Wednesday. Solventum has a fifty-two week low of $62.38 and a fifty-two week high of $88.20. The company has a debt-to-equity ratio of 0.96, a current ratio of 1.07 and a quick ratio of 0.89. The firm has a market capitalization of $12.69 billion, a price-to-earnings ratio of 8.98, a PEG ratio of 1.10 and a beta of 0.59. The company’s 50 day moving average price is $67.84 and its two-hundred day moving average price is $74.50.

Solventum (NYSE:SOLV) last posted its earnings results on Tuesday, May 5th. The company reported $1.48 earnings per share for the quarter, topping analysts’ consensus estimates of $1.35 by $0.13. The firm had revenue of $2.01 billion for the quarter, compared to analyst estimates of $1.97 billion. Solventum had a net margin of 17.33% and a return on equity of 23.51%. The company’s revenue for the quarter was down 3.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.34 EPS. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. As a group, research analysts predict that Solventum will post 6.59 earnings per share for the current year.

Insider Activity

In related news, Director Amy Mcbride Wendell bought 1,475 shares of the company’s stock in a transaction that occurred on Tuesday, March 10th. The shares were bought at an average price of $68.03 per share, for a total transaction of $100,344.25. Following the transaction, the director directly owned 5,039 shares of the company’s stock, valued at approximately $342,803.17. The trade was a 41.39% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.24% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Nordea Investment Management AB raised its holdings in shares of Solventum by 3.5% in the third quarter. Nordea Investment Management AB now owns 758,847 shares of the company’s stock valued at $54,880,000 after purchasing an additional 25,987 shares during the last quarter. LSV Asset Management raised its holdings in shares of Solventum by 364.5% in the third quarter. LSV Asset Management now owns 35,122 shares of the company’s stock valued at $2,564,000 after purchasing an additional 27,561 shares during the last quarter. Davis Selected Advisers raised its holdings in shares of Solventum by 0.5% in the third quarter. Davis Selected Advisers now owns 5,517,611 shares of the company’s stock valued at $402,786,000 after purchasing an additional 24,950 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. grew its position in Solventum by 15.3% during the third quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 307,789 shares of the company’s stock valued at $22,469,000 after buying an additional 40,812 shares during the period. Finally, Appleton Partners Inc. MA bought a new position in Solventum during the fourth quarter valued at about $7,008,000.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.